It has been reported that the intensity of the nodule in the HB phase of EOB-MRI is a promising imaging biomarker for predicting an unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC [16]. The gene discussed is CD274; the disease is hepatocellular carcinoma.